A method to predict the metabolic effects of changes in insulin treatment in subgroups of a large population based patient cohort
- 6 February 2007
- journal article
- research article
- Published by Springer Science and Business Media LLC in European Journal of Epidemiology
- Vol. 22 (3), 151-157
- https://doi.org/10.1007/s10654-007-9107-4
Abstract
This case-control study was designed to analyse predictors of the effects on HbA1c levels in 4001 type 1 and type 2 diabetic patients after changing their insulin treatment. Patients from 15 outpatient diabetic clinics were treated with basal insulin and multiple injections of short-acting insulin. The effects on HbA1c of changing from NPH insulin to insulin glargine as basal insulin were studied, compared to patients continuing with NPH insulin. The following possible predictors were examined with multiple regression analysis: age, sex, type and duration of diabetes, smoking, metformin use, insulin requirement, number of basal doses per day, BMI and HbA1c at baseline. The difference between the two regression functions yielded the effect of switching treatment to insulin glargine compared to continuing with NPH insulin. Male gender, low BMI and high baseline HbA1c levels were significant predictors for a greater decrease in HbA1c when changing to insulin glargine. For example, for men with a BMI of 25 and an HbA1c of 8.0%, there was a calculated mean benefit in HbA1c of 0.26 percentage points by changing to insulin glargine, whereas women with a BMI 30 had no benefit of such a change. Thus, changing to insulin glargine had best effect in male patients with low BMI. This is one of the first studies designed to find responders to insulin treatment. Analyses of predictors may prove useful in order to tailor insulin treatment in diabetic patients in clinical practice. The clinical effects need to be confirmed in other studies and randomised controlled trials.Keywords
This publication has 32 references indexed in Scilit:
- A randomized multicentre trial of insulin glargine compared with NPH insulin in people with type 1 diabetesDiabetes/Metabolism Research and Reviews, 2005
- Glargine is superior to neutral protamine Hagedorn for improving glycated haemoglobin and fasting blood glucose levels during intensive insulin therapyInternal Medicine Journal, 2005
- Optimization of basal insulin delivery in Type 1 diabetes: a retrospective study on the use of continuous subcutaneous insulin infusion and insulin glargineDiabetic Medicine, 2005
- Better long‐term glycaemic control with the basal insulin glargine as compared with NPH in patients with Type 1 diabetes mellitus given meal‐time lispro insulinDiabetic Medicine, 2004
- IFCC Reference System for Measurement of Hemoglobin A1c in Human Blood and the National Standardization Schemes in the United States, Japan, and Sweden: A Method-Comparison StudyClinical Chemistry, 2004
- A One-year, Randomised, Multicentre Trial Comparing Insulin Glargine with NPH Insulin in Combination with Oral Agents in Patients with Type 2 DiabetesHormone and Metabolic Research, 2003
- Confounding by Indication in Epidemiologic Studies of Commonly Used AnalgesicsClinical Journal of Sport Medicine, 2002
- Markers of Insulin Resistance Are Strong Risk Factors for Retinopathy Incidence in Type 1 Diabetes: The EURODIAB Prospective Complications StudyDiabetes Care, 2001
- Near-normal urinary albumin concentrations predict progression to diabetic nephropathy in Type 1 diabetes mellitusDiabetic Medicine, 2000
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998